Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial.
Maurer T, Belau MH, Zyriax BC, Welsch G, Jagemann B, Chang-Claude J, Daubmann A, Buchholz A, Glismann K, Moeller A, Sehouli J, Woopen H, Wimberger P, Harter P, Kaiser S, Maass N, Kiechle M, Engler T, Schmalfeldt B, Schulz H. Maurer T, et al. Among authors: sehouli j. BMC Cancer. 2024 Nov 11;24(1):1379. doi: 10.1186/s12885-024-13102-y. BMC Cancer. 2024. PMID: 39528997 Free PMC article.
The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.
Woopen H, Richter R, Inci G, Alavi S, Chekerov R, Sehouli J. Woopen H, et al. Among authors: sehouli j. Support Care Cancer. 2020 Apr;28(4):1997-2003. doi: 10.1007/s00520-019-05000-y. Epub 2019 Aug 5. Support Care Cancer. 2020. PMID: 31385100
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F. Harter P, et al. Among authors: sehouli j. Int J Gynecol Cancer. 2020 Dec;30(12):1997-2001. doi: 10.1136/ijgc-2020-001572. Epub 2020 Jun 30. Int J Gynecol Cancer. 2020. PMID: 32606097
Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients.
Armbrust R, Richter R, Woopen H, Hilpert F, Harter P, Sehouli J. Armbrust R, et al. Among authors: sehouli j. ESMO Open. 2021 Apr;6(2):100081. doi: 10.1016/j.esmoop.2021.100081. Epub 2021 Mar 18. ESMO Open. 2021. PMID: 33743329 Free PMC article.
The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Woopen H, Richter R, Chekerov R, Siepmann T, Ismaeel F, Sehouli J. Woopen H, et al. Among authors: sehouli j. Gynecol Oncol. 2015 Sep;138(3):735-40. doi: 10.1016/j.ygyno.2015.07.007. Epub 2015 Jul 13. Gynecol Oncol. 2015. PMID: 26185017
Lymphadenectomy in Advanced Ovarian Neoplasms. Reply.
Harter P, Sehouli J, du Bois A. Harter P, et al. Among authors: sehouli j. N Engl J Med. 2019 Jun 6;380(23):2274-2275. doi: 10.1056/NEJMc1904411. N Engl J Med. 2019. PMID: 31167063 No abstract available.
786 results